Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board.
Starting 1st October, Juan Carlos will succeed Wolfgang Bender, who will retire after a hand-over period, at the end of October.
Dr Juan Carlos Jaramillo has worked in various pharmaceutical/biotech organizations, including GlaxoSmithKline, Grünenthal and Daiichi Sankyo.
“I am delighted to be joining Valneva at an extremely exciting time. Valneva has a great and valuable portfolio of vaccines in development including chikungunya, Lyme and SARS-COV-2,” he said.
CEO Thomas Lingelbach added: “We are thrilled that Juan Carlos is joining Valneva. His expertise and multi-cultural leadership skills will be a great addition to the company. We sincerely thank Wolfgang for his outstanding leadership and his great contributions to the Company and its strategic development over the past four years.
“He has played a pivotal role in advancing the Company´s lead vaccine R&D programs against Lyme disease and Chikungunya and in building an excellent team. Everyone at Valneva wishes him very well in his retirement.”
